ANOVA	Analysis of variance
BC	Breast cancer
CBF1	Centromere-binding protein 1
CDDP	Cisplatin
CSL	CBF1/Su(H)/Lag-1
DCIs	Ductal carcinoma in situ
DRRCs	Log-probit dose–response relationship curves
Dll	Delta like ligand
DMSO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid
dnCSL	Dominant negative CSL
DSL	Delta, Serrate, Lag2
ER	Estrogen receptor
FBS	Fetal bovine serum
GSIs	γ-secretase inhibitors
HAT	Histone acetyltransferase
HDIs	Histone deacetylase inhibitors
HER2	Human epidermal growth factor receptor 2
HES1	HES family bHLH transcription factor 1
IDCs	Invasive ductal carcinomas
IHC	Immunohistochemistry
ILCs	Invasive lobular carcinomas
KDM5A	Lysine-specific demethylase 5A
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NICD	Intracellular domain of Notch receptor
PCAF	Acetyltransferase p300/CBP associated factor
PBS	Phosphate buffered saline
PR	Progesteron receptor
RBP-Jk	Recombination signal binding protein for immunoglobulin kappa
SAHA	Suberoylanilide hydroxamic acid
SHARP	SMART/HDAC1-associated repressor protein
SCLC	Small-cell lung carcinoma
SDS	Sodium dodecyl sulfate
S.E.M.	Standard error
SIRT1	Sirtuin 1
TNBC	Triple negative breast cancer
VPA	Valproic acid